Investors Target GeneDx Holdings in Securities Fraud Class Action

The litigation centers on claims that GeneDx executives misrepresented the synergy between its core operations and the Fabric business unit. Throughout the class period, the company suggested that combining these entities would optimize dry lab processes and reduce costs. However, the lawsuit alleges these projections were false, asserting that leadership either knew of or recklessly disregarded significant viability issues within Fabric that threatened the company’s broader financial health.

Those who suffered losses during this period have until August 3, 2026, to move the Court to serve as lead plaintiff. While a class action has been filed, no class has been certified, meaning investors are not currently represented by counsel unless they choose to retain one. Participation in any potential future recovery does not strictly require serving as a lead plaintiff, but those interested in directing the litigation are encouraged to contact Phillip Kim at Rosen Law Firm.